Leptomeningeal metastasis
- 1 November 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 22 (6), 627-635
- https://doi.org/10.1097/cco.0b013e32833de986
Abstract
Leptomeningeal metastasis occurs in approximately 3–5% of all patients with cancer. A contemporary literature review of methods of diagnosis and treatment of leptomeningeal metastasis was performed. The single most important aspect to diagnosis of leptomeningeal metastasis is considering and pursuing the diagnosis in a patient with cancer and neurological signs and symptoms. Evaluation of leptomeningeal metastasis includes contrast-enhanced brain and spine magnetic resonance imaging (MRI) and a radionuclide cerebrospinal fluid (CSF) flow study if leptomeningeal metastasis-directed therapy is being considered. Treatment often requires involved-field radiotherapy to bulky or symptomatic disease sites as well as intra-CSF and systemic chemotherapy. The use of high-dose systemic therapy may benefit patients with leptomeningeal metastasis and obviate the need for intra-CSF chemotherapy. Intra-CSF drug therapy primarily utilizes one of three chemotherapeutic agents (i.e. methotrexate, cytosine arabinoside and thio-TEPA) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Novel and increasingly utilized intra-CSF agents in the treatment of leptomeningeal metastasis are targeted monoclonal antibodies such as rituximab and trastuzumab. Although treatment of leptomeningeal metastasis is palliative with median patient survival of 2–3 months (15% of patients with leptomeningeal metastasis survive 1 year), treatment may afford stabilization and protection from further neurologic deterioration in patients with leptomeningeal metastasis.Keywords
This publication has 96 references indexed in Scilit:
- Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapyJournal of Neuro-Oncology, 2009
- Prognostic factors and outcomes in patients with leptomeningeal melanomatosisNeuro-Oncology, 2008
- Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case reportAnti-Cancer Drugs, 2008
- A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesNeuro-Oncology, 2008
- Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical featuresNeuro-Oncology, 2008
- Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossaJournal of Neurosurgery, 2008
- New Agents for Intrathecal AdministrationCancer Investigation, 2006
- Ventriculoperitoneal shunt in patients with leptomeningeal metastasisNeurology, 2005
- The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised studyEuropean Journal Of Cancer, 2004
- Comparative spine imaging in leptomeningeal metastasesJournal of Neuro-Oncology, 1995